Statement of Changes in Beneficial Ownership (4)
February 19 2020 - 6:14PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Galdes Alphonse |
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC.
[
BIIB
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP Pharmaceutical Oper & Tech |
(Last)
(First)
(Middle)
BIOGEN INC., 225 BINNEY STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/15/2020 |
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 2/15/2020 | | M | | 441 | A | $0 | 2672.264 | D | |
Common Stock | 2/15/2020 | | F | | 130 | D | $333.00 | 2542.264 | D | |
Common Stock | | | | | | | | 969.366 | I | By spouse |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Restricted Stock Unit | $0 | 2/15/2020 | | M | | | 441 | (1) | 2/15/2020 | Common Stock | 441 | $0 | 333 | D | |
Restricted Stock Unit | $0 | 2/15/2020 | | J | | | 333 (2) | (1) | 2/15/2020 | Common Stock | 333 | $0 | 0 | D | |
Explanation of Responses: |
(1) | The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
(2) | This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Galdes Alphonse BIOGEN INC. 225 BINNEY STREET CAMBRIDGE, MA 02142 |
|
| EVP Pharmaceutical Oper & Tech |
|
Signatures
|
/s/ Suzanne Murray, Attorney in Fact for Alphonse Galdes | | 2/19/2020 |
**Signature of Reporting Person | Date |
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Sep 2023 to Sep 2024